<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02439749</url>
  </required_header>
  <id_info>
    <org_study_id>SPYRAL HTN-OFF MED</org_study_id>
    <nct_id>NCT02439749</nct_id>
  </id_info>
  <brief_title>SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study</brief_title>
  <official_title>Global Clinical Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension in the Absence of Antihypertensive Medications (SPYRAL PIVOTAL - SPYRAL HTN-OFF MED)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the hypothesis that renal denervation decreases blood&#xD;
      pressure and is safe when studied in the absence of antihypertensive medications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Major Adverse Events (MAE) Defined as a Composite of Events.</measure>
    <time_frame>From baseline to 1 month post-procedure</time_frame>
    <description>All-cause mortality End-stage Renal Disease (ESRD) Significant embolic event resulting in end-organ damage Renal artery perforation requiring intervention Renal artery dissection requiring intervention Vascular complications Hospitalization for hypertensive crisis not related to confirmed non-adherence with medications or the protocol New renal artery stenosis &gt;70% (6 months for new renal artery stenosis, however endpoint data is reported to 3 months only)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Adjusted Change (Using Analysis of Covariance) in Systolic Blood Pressure as Measured by 24-hour Ambulatory Blood Pressure Monitoring</measure>
    <time_frame>From baseline to 3 months post-procedure</time_frame>
    <description>The outcome measure is the change in ambulatory systolic blood pressure from baseline to 3-month. The unadjusted treatment difference between renal denervation and sham control groups is -3.9 mmHg. The baseline adjusted treatment difference is -3.9 mmHg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline Adjusted Change (Using Analysis of Covariance) in Office Systolic Blood Pressure</measure>
    <time_frame>From baseline to 3 months post-procedure</time_frame>
    <description>The outcome measure is the change in office systolic blood pressure from baseline to 3-month. The unadjusted treatment difference between renal denervation and sham control groups is -7.0 mmHg. The baseline adjusted treatment difference is -6.9 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Significant Embolic Event Resulting in End-organ Damage</measure>
    <time_frame>From baseline to 1 month post-procedure</time_frame>
    <description>Significant embolic event resulting in end-organ damage (e.g. kidney/bowel infarct, lower extremity ulceration or gangrene, or doubling of serum creatinine documented by at least two measurements at least 21 days apart)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Renal Artery Perforation Requiring Intervention</measure>
    <time_frame>From baseline to 1 month post-procedure</time_frame>
    <description>Renal artery perforation requiring intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Artery Dissection</measure>
    <time_frame>From baseline to 1 month post-procedure</time_frame>
    <description>Number of Participants with Renal artery dissection requiring intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Vascular Complications</measure>
    <time_frame>From baseline to 1 month post-procedure</time_frame>
    <description>Vascular complications (e.g., clinically significant groin hematoma, arteriovenous fistula, pseudoaneurysm, excessive bleeding) requiring surgical repair, interventional procedure, thrombin injection, or blood transfusion (requiring more than 2 units of packed red blood cells within any 24 hour period during the first 7 days post renal denervation procedure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With End-stage Renal Disease</measure>
    <time_frame>From baseline to 1 month post-procedure</time_frame>
    <description>defined as two or more eGFR measurements &lt; 15 mL/min/1.73m2 at least 21 days apart and requiring dialysis for one of more of the following:&#xD;
Volume management refractory to diuretics&#xD;
Hyperkalemia unmanageable by diet and diuretics&#xD;
Acidosis bicarbonate &lt;18 unmanageable with HCO3 supplements&#xD;
Symptoms of uremia, nausea, vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Decline in eGFR</measure>
    <time_frame>From baseline to 1 month post-procedure</time_frame>
    <description>≥40% decline in eGFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>From baseline to 1 month post-procedure</time_frame>
    <description>Number of Participants with New myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New Stroke</measure>
    <time_frame>From baseline to 1 month post-procedure</time_frame>
    <description>Number of Participants with New stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Renal Artery Re-intervention</measure>
    <time_frame>From baseline to 1 month post-procedure</time_frame>
    <description>Renal artery re-intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Major Bleeding According to TIMI Definition</measure>
    <time_frame>From baseline to 1 month post-procedure</time_frame>
    <description>Major bleeding according to TIMI definition (i.e. intracranial hemorrhage, ≥5g/dl decrease in hemoglobin concentration, a ≥15% absolute decrease in hematocrit, or death due to bleeding within 7 days of the procedure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Increase in Serum Creatinine</measure>
    <time_frame>From baseline to 1 month post-procedure</time_frame>
    <description>Increase in serum creatinine &gt; 50% from screening visit 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New Renal Artery Stenosis &gt; 70%</measure>
    <time_frame>From baseline to 6 month post-procedure</time_frame>
    <description>Confirmed by angiography and as determined by the angiographic core laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hospitalization for Hypertensive Crisis With Medications or the Protocol</measure>
    <time_frame>From baseline to 1 month post-procedure</time_frame>
    <description>Hospitalization for hypertensive crisis not related to confirmed non-adherence with medications or the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-cause Mortality</measure>
    <time_frame>From baseline to 3 months post-procedure</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Systolic Blood Pressure as Measured by 24-hour ABPM</measure>
    <time_frame>From baseline to 36 month post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Incidence of Achieving Target Office Systolic Blood Pressure (SBP &lt;140 mmHg)</measure>
    <time_frame>From 1 month to 36 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Office Diastolic Blood Pressure</measure>
    <time_frame>From baseline to 36 months post-procedure</time_frame>
    <description>Change in office diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Diastolic Blood Pressure as Measured by 24-hour ABPM</measure>
    <time_frame>From baseline to 36 months post-procedure</time_frame>
    <description>Change in diastolic blood pressure as measured by 24-hour ABPM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With End-Stage Renal Disease (ESRD)</measure>
    <time_frame>From baseline to 3 months post randomization</time_frame>
    <description>Defined as two or more eGFR measurements &lt; 15 mL/min/1.73m2 at least 21 days apart and requiring dialysis for one of more of the following:&#xD;
Volume management refractory to diuretics&#xD;
Hyperkalemia unmanageable by diet and diuretics&#xD;
Acidosis bicarbonate &lt;18 unmanageable with HCO3 supplements&#xD;
Symptoms of uremia, nausea, vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ≥40% Decline in eGFR</measure>
    <time_frame>From baseline to 3 months post randomization</time_frame>
    <description>≥40% Decline in eGFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New Myocardial Infarction</measure>
    <time_frame>From baseline to 3 months post randomization</time_frame>
    <description>New Myocardial Infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New Stroke</measure>
    <time_frame>From baseline to 3 months post randomization</time_frame>
    <description>Number of Participants with New Stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Renal Artery Re-intervention</measure>
    <time_frame>From baseline to 3 months post randomization</time_frame>
    <description>Renal Artery Re-intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Major Bleeding According to TIMI Definition</measure>
    <time_frame>From baseline to 3 months post randomization</time_frame>
    <description>Major bleeding according to TIMI definition (i.e. intracranial hemorrhage, ≥5g/dl decrease in hemoglobin concentration, a ≥15% absolute decrease in hematocrit, or death due to bleeding within 7 days of the procedure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in Serum Creatinine</measure>
    <time_frame>From baseline to 3 months post randomization</time_frame>
    <description>Number of Participants with Increase in Serum Creatinine &gt; 50% from screening visit 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hospitalization for Hypertensive Crisis</measure>
    <time_frame>From baseline to 3 months post randomization</time_frame>
    <description>Hospitalization for Hypertensive Crisis Not Related to Confirmed Nonadherence With Medications or the Protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Office Systolic Blood Pressure</measure>
    <time_frame>From baseline to 1 month post procedure</time_frame>
    <description>Change in office systolic blood pressure from baseline (Screening Visit 2) to 1-month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Target Office Systolic Blood Pressure</measure>
    <time_frame>From baseline to 1 month post procedure</time_frame>
    <description>Incidence of achieving target office systolic blood pressure (SBP &lt;140 mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Target Office Systolic Blood Pressure</measure>
    <time_frame>From baseline to 3 months post procedure</time_frame>
    <description>Incidence of Achieving Target Office Systolic Blood Pressure (SBP &lt;140 mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Office Diastolic Blood Pressure</measure>
    <time_frame>From baseline to 1 month post procedure</time_frame>
    <description>Change in office diastolic blood pressure from baseline (Screening Visit 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Office Diastolic Blood Pressure</measure>
    <time_frame>From baseline to 3 months post procedure</time_frame>
    <description>Change in Office Diastolic Blood Pressure From Baseline (Screening Visit 2) to 3-months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Blood Pressure as Measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM)</measure>
    <time_frame>From baseline to 3 months post procedure</time_frame>
    <description>Change in diastolic blood pressure from baseline (screening visit 2) to 3-month as measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">366</enrollment>
  <condition>Hypertension</condition>
  <condition>Vascular Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Renal Denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Procedure</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Renal angiography</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Symplicity Spyral™ multi-electrode renal denervation system</intervention_name>
    <description>After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
    <arm_group_label>Renal Denervation</arm_group_label>
    <other_name>Renal angiography</other_name>
    <other_name>Renal Denervation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham Procedure</intervention_name>
    <description>After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
    <arm_group_label>Sham Procedure</arm_group_label>
    <other_name>Renal angiography</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individual has office systolic blood pressure (SBP) ≥ 150 mmHg and &lt;180 mmHg and a&#xD;
             diastolic blood pressure (DBP) ≥ 90 mmHg after being off medications.&#xD;
&#xD;
          -  Individual has 24-hour Ambulatory Blood Pressure Monitoring (ABPM) average SBP ≥ 140&#xD;
             mmHg and &lt; 170 mmHg.&#xD;
&#xD;
          -  Individual is willing to discontinue current antihypertensive medications.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individual lacks appropriate renal artery anatomy.&#xD;
&#xD;
          -  Individual has estimated glomerular filtration rate (eGFR) of &lt;45.&#xD;
&#xD;
          -  Individual has type 1 diabetes mellitus or poorly-controlled type 2 diabetes mellitus.&#xD;
&#xD;
          -  Individual has one or more episodes of orthostatic hypotension.&#xD;
&#xD;
          -  Individual requires chronic oxygen support or mechanical ventilation other than&#xD;
             nocturnal respiratory support for sleep apnea.&#xD;
&#xD;
          -  Individual has primary pulmonary hypertension.&#xD;
&#xD;
          -  Individual is pregnant, nursing or planning to become pregnant.&#xD;
&#xD;
          -  Individual has frequent intermittent or chronic pain that results in treatment with&#xD;
             nonsteroidal anti-inflammatory drugs (NSAIDs) for two or more days per week over the&#xD;
             month prior to enrollment.&#xD;
&#xD;
          -  Individual has stable or unstable angina within 3 months of enrollment, myocardial&#xD;
             infarction within 3 months of enrollment; heart failure, cerebrovascular accident or&#xD;
             transient ischemic attack, or atrial fibrillation at any time.&#xD;
&#xD;
          -  Individual works night shifts.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Townsend, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Kandzari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Piedmont Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Böhm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätskliniken des Saarlandes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kazuomi Kario, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jichi Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart Center Research, LLC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Honor Health Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente LA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tallahassee Research Institute</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Heart Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Heart Center</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Joseph Mercy Oakland</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Hospital</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Associates Research LLC</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Barnabas Medical Center</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PinnacleHealth Cardiovascular Institute</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AnMed Health</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centennial Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Heart &amp; Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Area Medical Center</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de cardiologie de Montréal / Montreal Heart Institute</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg - Bad Krozingen GmbH</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig, Universitätsklinik</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sana Kliniken Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23560</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hippokration General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Thessaloniki (AHEPA)</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54621</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galway University Hospital</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospital</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mitsui Memorial Hospital</name>
      <address>
        <city>Chiyoda</city>
        <state>Tokyo</state>
        <zip>101-8643</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiff and Vale University Health Board - University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon &amp; Exeter NHS Foundation Trust</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Japan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 28, 2015</study_first_submitted>
  <study_first_submitted_qc>May 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2015</study_first_posted>
  <results_first_submitted>April 30, 2021</results_first_submitted>
  <results_first_submitted_qc>April 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 27, 2021</results_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uncontrolled hypertension</keyword>
  <keyword>Renal denervation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 22, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT02439749/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 6, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT02439749/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Renal Denervation</title>
          <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
        </group>
        <group group_id="P2">
          <title>Sham Procedure</title>
          <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="182"/>
                <participants group_id="P2" count="184"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Renal Denervation</title>
          <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
        </group>
        <group group_id="B2">
          <title>Sham Procedure</title>
          <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="182"/>
            <count group_id="B2" value="184"/>
            <count group_id="B3" value="366"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="325"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.5" spread="10.8"/>
                    <measurement group_id="B2" value="52.7" spread="10.1"/>
                    <measurement group_id="B3" value="52.6" spread="10.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Japanese from Japan</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ireland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Major Adverse Events (MAE) Defined as a Composite of Events.</title>
        <description>All-cause mortality End-stage Renal Disease (ESRD) Significant embolic event resulting in end-organ damage Renal artery perforation requiring intervention Renal artery dissection requiring intervention Vascular complications Hospitalization for hypertensive crisis not related to confirmed non-adherence with medications or the protocol New renal artery stenosis &gt;70% (6 months for new renal artery stenosis, however endpoint data is reported to 3 months only)</description>
        <time_frame>From baseline to 1 month post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Adverse Events (MAE) Defined as a Composite of Events.</title>
          <description>All-cause mortality End-stage Renal Disease (ESRD) Significant embolic event resulting in end-organ damage Renal artery perforation requiring intervention Renal artery dissection requiring intervention Vascular complications Hospitalization for hypertensive crisis not related to confirmed non-adherence with medications or the protocol New renal artery stenosis &gt;70% (6 months for new renal artery stenosis, however endpoint data is reported to 3 months only)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline Adjusted Change (Using Analysis of Covariance) in Systolic Blood Pressure as Measured by 24-hour Ambulatory Blood Pressure Monitoring</title>
        <description>The outcome measure is the change in ambulatory systolic blood pressure from baseline to 3-month. The unadjusted treatment difference between renal denervation and sham control groups is -3.9 mmHg. The baseline adjusted treatment difference is -3.9 mmHg.</description>
        <time_frame>From baseline to 3 months post-procedure</time_frame>
        <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Adjusted Change (Using Analysis of Covariance) in Systolic Blood Pressure as Measured by 24-hour Ambulatory Blood Pressure Monitoring</title>
          <description>The outcome measure is the change in ambulatory systolic blood pressure from baseline to 3-month. The unadjusted treatment difference between renal denervation and sham control groups is -3.9 mmHg. The baseline adjusted treatment difference is -3.9 mmHg.</description>
          <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="10.8"/>
                    <measurement group_id="O2" value="-0.6" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Adjusted Change (Using Analysis of Covariance) in Office Systolic Blood Pressure</title>
        <description>The outcome measure is the change in office systolic blood pressure from baseline to 3-month. The unadjusted treatment difference between renal denervation and sham control groups is -7.0 mmHg. The baseline adjusted treatment difference is -6.9 mmHg.</description>
        <time_frame>From baseline to 3 months post-procedure</time_frame>
        <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Adjusted Change (Using Analysis of Covariance) in Office Systolic Blood Pressure</title>
          <description>The outcome measure is the change in office systolic blood pressure from baseline to 3-month. The unadjusted treatment difference between renal denervation and sham control groups is -7.0 mmHg. The baseline adjusted treatment difference is -6.9 mmHg.</description>
          <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.3" spread="14.7"/>
                    <measurement group_id="O2" value="-2.3" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Significant Embolic Event Resulting in End-organ Damage</title>
        <description>Significant embolic event resulting in end-organ damage (e.g. kidney/bowel infarct, lower extremity ulceration or gangrene, or doubling of serum creatinine documented by at least two measurements at least 21 days apart)</description>
        <time_frame>From baseline to 1 month post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Significant Embolic Event Resulting in End-organ Damage</title>
          <description>Significant embolic event resulting in end-organ damage (e.g. kidney/bowel infarct, lower extremity ulceration or gangrene, or doubling of serum creatinine documented by at least two measurements at least 21 days apart)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Renal Artery Perforation Requiring Intervention</title>
        <description>Renal artery perforation requiring intervention</description>
        <time_frame>From baseline to 1 month post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Renal Artery Perforation Requiring Intervention</title>
          <description>Renal artery perforation requiring intervention</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Artery Dissection</title>
        <description>Number of Participants with Renal artery dissection requiring intervention</description>
        <time_frame>From baseline to 1 month post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Artery Dissection</title>
          <description>Number of Participants with Renal artery dissection requiring intervention</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Vascular Complications</title>
        <description>Vascular complications (e.g., clinically significant groin hematoma, arteriovenous fistula, pseudoaneurysm, excessive bleeding) requiring surgical repair, interventional procedure, thrombin injection, or blood transfusion (requiring more than 2 units of packed red blood cells within any 24 hour period during the first 7 days post renal denervation procedure).</description>
        <time_frame>From baseline to 1 month post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vascular Complications</title>
          <description>Vascular complications (e.g., clinically significant groin hematoma, arteriovenous fistula, pseudoaneurysm, excessive bleeding) requiring surgical repair, interventional procedure, thrombin injection, or blood transfusion (requiring more than 2 units of packed red blood cells within any 24 hour period during the first 7 days post renal denervation procedure).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With End-stage Renal Disease</title>
        <description>defined as two or more eGFR measurements &lt; 15 mL/min/1.73m2 at least 21 days apart and requiring dialysis for one of more of the following:&#xD;
Volume management refractory to diuretics&#xD;
Hyperkalemia unmanageable by diet and diuretics&#xD;
Acidosis bicarbonate &lt;18 unmanageable with HCO3 supplements&#xD;
Symptoms of uremia, nausea, vomiting</description>
        <time_frame>From baseline to 1 month post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With End-stage Renal Disease</title>
          <description>defined as two or more eGFR measurements &lt; 15 mL/min/1.73m2 at least 21 days apart and requiring dialysis for one of more of the following:&#xD;
Volume management refractory to diuretics&#xD;
Hyperkalemia unmanageable by diet and diuretics&#xD;
Acidosis bicarbonate &lt;18 unmanageable with HCO3 supplements&#xD;
Symptoms of uremia, nausea, vomiting</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Decline in eGFR</title>
        <description>≥40% decline in eGFR</description>
        <time_frame>From baseline to 1 month post-procedure</time_frame>
        <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Decline in eGFR</title>
          <description>≥40% decline in eGFR</description>
          <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction</title>
        <description>Number of Participants with New myocardial infarction</description>
        <time_frame>From baseline to 1 month post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction</title>
          <description>Number of Participants with New myocardial infarction</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New Stroke</title>
        <description>Number of Participants with New stroke</description>
        <time_frame>From baseline to 1 month post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>New Stroke</title>
          <description>Number of Participants with New stroke</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Renal Artery Re-intervention</title>
        <description>Renal artery re-intervention</description>
        <time_frame>From baseline to 1 month post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Renal Artery Re-intervention</title>
          <description>Renal artery re-intervention</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Major Bleeding According to TIMI Definition</title>
        <description>Major bleeding according to TIMI definition (i.e. intracranial hemorrhage, ≥5g/dl decrease in hemoglobin concentration, a ≥15% absolute decrease in hematocrit, or death due to bleeding within 7 days of the procedure).</description>
        <time_frame>From baseline to 1 month post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Bleeding According to TIMI Definition</title>
          <description>Major bleeding according to TIMI definition (i.e. intracranial hemorrhage, ≥5g/dl decrease in hemoglobin concentration, a ≥15% absolute decrease in hematocrit, or death due to bleeding within 7 days of the procedure).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Increase in Serum Creatinine</title>
        <description>Increase in serum creatinine &gt; 50% from screening visit 2.</description>
        <time_frame>From baseline to 1 month post-procedure</time_frame>
        <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Increase in Serum Creatinine</title>
          <description>Increase in serum creatinine &gt; 50% from screening visit 2.</description>
          <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New Renal Artery Stenosis &gt; 70%</title>
        <description>Confirmed by angiography and as determined by the angiographic core laboratory.</description>
        <time_frame>From baseline to 6 month post-procedure</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hospitalization for Hypertensive Crisis With Medications or the Protocol</title>
        <description>Hospitalization for hypertensive crisis not related to confirmed non-adherence with medications or the protocol.</description>
        <time_frame>From baseline to 1 month post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hospitalization for Hypertensive Crisis With Medications or the Protocol</title>
          <description>Hospitalization for hypertensive crisis not related to confirmed non-adherence with medications or the protocol.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All-cause Mortality</title>
        <description>All-cause mortality</description>
        <time_frame>From baseline to 3 months post-procedure</time_frame>
        <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-cause Mortality</title>
          <description>All-cause mortality</description>
          <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Systolic Blood Pressure as Measured by 24-hour ABPM</title>
        <time_frame>From baseline to 36 month post-procedure</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Incidence of Achieving Target Office Systolic Blood Pressure (SBP &lt;140 mmHg)</title>
        <time_frame>From 1 month to 36 months post-procedure</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Office Diastolic Blood Pressure</title>
        <description>Change in office diastolic blood pressure</description>
        <time_frame>From baseline to 36 months post-procedure</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Diastolic Blood Pressure as Measured by 24-hour ABPM</title>
        <description>Change in diastolic blood pressure as measured by 24-hour ABPM</description>
        <time_frame>From baseline to 36 months post-procedure</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With End-Stage Renal Disease (ESRD)</title>
        <description>Defined as two or more eGFR measurements &lt; 15 mL/min/1.73m2 at least 21 days apart and requiring dialysis for one of more of the following:&#xD;
Volume management refractory to diuretics&#xD;
Hyperkalemia unmanageable by diet and diuretics&#xD;
Acidosis bicarbonate &lt;18 unmanageable with HCO3 supplements&#xD;
Symptoms of uremia, nausea, vomiting</description>
        <time_frame>From baseline to 3 months post randomization</time_frame>
        <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With End-Stage Renal Disease (ESRD)</title>
          <description>Defined as two or more eGFR measurements &lt; 15 mL/min/1.73m2 at least 21 days apart and requiring dialysis for one of more of the following:&#xD;
Volume management refractory to diuretics&#xD;
Hyperkalemia unmanageable by diet and diuretics&#xD;
Acidosis bicarbonate &lt;18 unmanageable with HCO3 supplements&#xD;
Symptoms of uremia, nausea, vomiting</description>
          <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ≥40% Decline in eGFR</title>
        <description>≥40% Decline in eGFR</description>
        <time_frame>From baseline to 3 months post randomization</time_frame>
        <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ≥40% Decline in eGFR</title>
          <description>≥40% Decline in eGFR</description>
          <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New Myocardial Infarction</title>
        <description>New Myocardial Infarction</description>
        <time_frame>From baseline to 3 months post randomization</time_frame>
        <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New Myocardial Infarction</title>
          <description>New Myocardial Infarction</description>
          <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New Stroke</title>
        <description>Number of Participants with New Stroke</description>
        <time_frame>From baseline to 3 months post randomization</time_frame>
        <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>New Stroke</title>
          <description>Number of Participants with New Stroke</description>
          <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Renal Artery Re-intervention</title>
        <description>Renal Artery Re-intervention</description>
        <time_frame>From baseline to 3 months post randomization</time_frame>
        <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Renal Artery Re-intervention</title>
          <description>Renal Artery Re-intervention</description>
          <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Major Bleeding According to TIMI Definition</title>
        <description>Major bleeding according to TIMI definition (i.e. intracranial hemorrhage, ≥5g/dl decrease in hemoglobin concentration, a ≥15% absolute decrease in hematocrit, or death due to bleeding within 7 days of the procedure).</description>
        <time_frame>From baseline to 3 months post randomization</time_frame>
        <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Bleeding According to TIMI Definition</title>
          <description>Major bleeding according to TIMI definition (i.e. intracranial hemorrhage, ≥5g/dl decrease in hemoglobin concentration, a ≥15% absolute decrease in hematocrit, or death due to bleeding within 7 days of the procedure).</description>
          <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Increase in Serum Creatinine</title>
        <description>Number of Participants with Increase in Serum Creatinine &gt; 50% from screening visit 2.</description>
        <time_frame>From baseline to 3 months post randomization</time_frame>
        <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Increase in Serum Creatinine</title>
          <description>Number of Participants with Increase in Serum Creatinine &gt; 50% from screening visit 2.</description>
          <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hospitalization for Hypertensive Crisis</title>
        <description>Hospitalization for Hypertensive Crisis Not Related to Confirmed Nonadherence With Medications or the Protocol</description>
        <time_frame>From baseline to 3 months post randomization</time_frame>
        <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hospitalization for Hypertensive Crisis</title>
          <description>Hospitalization for Hypertensive Crisis Not Related to Confirmed Nonadherence With Medications or the Protocol</description>
          <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Office Systolic Blood Pressure</title>
        <description>Change in office systolic blood pressure from baseline (Screening Visit 2) to 1-month</description>
        <time_frame>From baseline to 1 month post procedure</time_frame>
        <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Office Systolic Blood Pressure</title>
          <description>Change in office systolic blood pressure from baseline (Screening Visit 2) to 1-month</description>
          <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.2" spread="14.0"/>
                    <measurement group_id="O2" value="-5.7" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Target Office Systolic Blood Pressure</title>
        <description>Incidence of achieving target office systolic blood pressure (SBP &lt;140 mmHg)</description>
        <time_frame>From baseline to 1 month post procedure</time_frame>
        <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Target Office Systolic Blood Pressure</title>
          <description>Incidence of achieving target office systolic blood pressure (SBP &lt;140 mmHg)</description>
          <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Target Office Systolic Blood Pressure</title>
        <description>Incidence of Achieving Target Office Systolic Blood Pressure (SBP &lt;140 mmHg)</description>
        <time_frame>From baseline to 3 months post procedure</time_frame>
        <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Target Office Systolic Blood Pressure</title>
          <description>Incidence of Achieving Target Office Systolic Blood Pressure (SBP &lt;140 mmHg)</description>
          <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Office Diastolic Blood Pressure</title>
        <description>Change in office diastolic blood pressure from baseline (Screening Visit 2)</description>
        <time_frame>From baseline to 1 month post procedure</time_frame>
        <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Office Diastolic Blood Pressure</title>
          <description>Change in office diastolic blood pressure from baseline (Screening Visit 2)</description>
          <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="8.3"/>
                    <measurement group_id="O2" value="-2.8" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Office Diastolic Blood Pressure</title>
        <description>Change in Office Diastolic Blood Pressure From Baseline (Screening Visit 2) to 3-months</description>
        <time_frame>From baseline to 3 months post procedure</time_frame>
        <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Office Diastolic Blood Pressure</title>
          <description>Change in Office Diastolic Blood Pressure From Baseline (Screening Visit 2) to 3-months</description>
          <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.3" spread="14.7"/>
                    <measurement group_id="O2" value="-2.3" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diastolic Blood Pressure as Measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM)</title>
        <description>Change in diastolic blood pressure from baseline (screening visit 2) to 3-month as measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM).</description>
        <time_frame>From baseline to 3 months post procedure</time_frame>
        <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
        <group_list>
          <group group_id="O1">
            <title>Renal Denervation</title>
            <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Sham Procedure</title>
            <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure as Measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM)</title>
          <description>Change in diastolic blood pressure from baseline (screening visit 2) to 3-month as measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM).</description>
          <population>The number of participants analyzed reflects the number of subjects within each treatment arm who have data available for outcome measure analysis. This number can be variable from the number of subjects in each treatment arm at study start.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="6.7"/>
                    <measurement group_id="O2" value="-0.8" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Renal Denervation</title>
          <description>Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)&#xD;
Symplicity Spyral™ multi-electrode renal denervation system: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.</description>
        </group>
        <group group_id="E2">
          <title>Sham Procedure</title>
          <description>Renal angiography&#xD;
Sham Procedure: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Tendon Rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Vascular Access Site Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Vertebral Foraminal Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Carpal Tunnel Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Primary Headache Associated With Sexual Activity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular Access Site Haematoma</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="182"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="27" subjects_affected="22" subjects_at_risk="182"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pamela McKenna, Sr. Principal Clinical Research Specialist</name_or_title>
      <organization>Medtronic</organization>
      <phone>(773) 597-5241</phone>
      <email>pamela.m.mckenna@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

